Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. has 1 licensing announcement in this dataset, dated 2026-04-01.
- Country / operating region
- Japan
- Ticker
- 4568.T
- Headquarters
- Tokyo, Japan
- Founded
- 2005
- Business
- Pharmaceutical research and development
- Website
- www.daiichisankyo.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| DS-1001b / DS-1001a | Mutant IDH1 | small molecule | phase3 | 2026-04-01 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| DS-1062a / Dato-DXd | PHASE3 | NCT05374512 | ACTIVE_NOT_RECRUITING | AstraZeneca | 2026-05-15 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-04-01 | Nuvation Bio Inc. | DS-1001b / DS-1001a | 查無 | 查無 | 查無 | 查無 | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Nuvation Bio Inc. | Japan (additional territory; licensee now holds worldwide rights) | 查無 |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無